Every material Form 8-K Labcorp filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Labcorp said Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer, notified the company on December 9, 2025, of his intention to retire. His retirement takes effect April 1, 2026, giving the company about three months to plan for the departure of a senior operating executive.
Mark Schroeder notified Labcorp of his retirement on December 9, 2025.
Retirement is effective April 1, 2026.
Schroeder held the roles of EVP and President, Diagnostics Laboratories, and Chief Operations Officer.
The filing does not name a successor or describe any compensation arrangements.
Labcorp announced that director Dr. D. Gary Gilliland will retire from its board effective December 31, 2025, having notified the board on December 5, 2025. The filing reports no financial results, no successor named, and no change in company guidance, so the direct effect on shareholders appears limited to board composition.
Dr. D. Gary Gilliland notified the board of his retirement decision on December 5, 2025; the retirement takes effect December 31, 2025.
Gilliland joined the board in 2014 and served on the Audit Committee and Quality and Compliance Committee.
Chairman and CEO Adam Schechter credited Gilliland with more than 10 years of service; lead independent director Dr. Garheng Kong cited his leadership and strategic insight.
Labcorp's Board of Directors appointed Victor Bulto, President of Novartis U.S. and a member of the Novartis Executive Committee, as a director effective December 1, 2025. The filing describes the appointment as a board addition and includes no financial results, guidance, or changes to executive roles.
Board appointment made on November 20, 2025, effective December 1, 2025
Bulto has served as President of Novartis U.S. and on the Novartis Executive Committee since April 2022
Bulto will receive director compensation under Labcorp's director compensation program described in the April 4, 2025 proxy statement
Labcorp reported third-quarter 2025 revenue of $3.56 billion, up from $3.28 billion, and diluted EPS of $3.12, up from $2.00. It raised its full-year adjusted EPS guidance midpoint by $0.05 and its free cash flow guidance midpoint by $25 million, but lowered its revenue growth guidance midpoint by 40 basis points, citing currency and acquisition timing.
Q3 revenue was $3.56 billion versus $3.28 billion a year earlier; adjusted EPS was $4.18 versus $3.50.
Full-year adjusted EPS guidance is now $16.15 to $16.50, with the midpoint raised by $0.05.
Full-year revenue growth guidance is 7.4% to 8.0%, with the midpoint lowered 40 basis points due to currency and acquisition timing.
Free cash flow guidance is $1.17 billion to $1.29 billion, with the midpoint raised by $25 million.
Labcorp reported second-quarter 2025 revenue of $3.53 billion, up from $3.22 billion a year earlier, and diluted EPS of $2.84 versus $2.43. The company raised its full-year 2025 guidance for enterprise revenue, adjusted EPS and free cash flow, which is a positive signal for shareholders on both sales and earnings.
Q2 revenue $3.53 billion vs $3.22 billion; diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94
Adjusted EPS guidance range narrowed to $16.05 to $16.50 from $15.70 to $16.40; midpoint raised by $0.23
Free cash flow guidance of $1.13 billion to $1.28 billion, midpoint raised by $25 million
Quarterly dividend of $0.72 per share declared July 10, 2025, payable September 11, 2025; $200 million of stock repurchased in the quarter
On June 27, 2025, Labcorp Holdings and its subsidiary Laboratory Corporation of America Holdings entered a Fourth Amended and Restated Credit Agreement with Bank of America as administrative agent. The $1 billion senior unsecured revolving facility replaces the existing facility and extends its maturity from April 30, 2026 to June 27, 2030. The company had no outstanding borrowings under the facility as of the closing date.
Facility size of $1,000,000,000, including a $100,000,000 swingline subfacility and a $150,000,000 letter of credit sublimit
Maturity extended from April 30, 2026 to June 27, 2030
No outstanding borrowings as of June 27, 2025; the facility can be increased by up to $500,000,000, subject to conditions
Financial covenant requires a leverage ratio of not more than 4.0 to 1.0, with a temporary increase to 4.5 to 1.0 after a material acquisition
At its 2025 Annual Meeting on May 15, 2025, Labcorp shareholders elected all 10 director nominees to terms expiring at the 2026 meeting and approved the 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan. Shareholders also ratified Deloitte & Touche LLP as the independent auditor for 2025 and approved executive pay in an advisory vote.
Holders of 76,049,607 of 83,668,573 shares on the March 20, 2025 record date were represented, meeting the quorum.
The 2025 Omnibus Incentive Plan received 65,957,167 votes for and 3,916,664 against.
The 2025 Employee Stock Purchase Plan received 69,852,552 votes for and 111,189 against.
Deloitte & Touche LLP was ratified for the year ending December 31, 2025, with 75,696,303 votes for and 297,066 against.
Labcorp reported first-quarter 2025 revenue of $3.35 billion, up from $3.18 billion a year earlier, and adjusted EPS of $3.84, up from $3.68. GAAP diluted EPS fell to $2.52 from $2.69. The company raised the midpoint of its full-year adjusted EPS guidance by $0.05 and reaffirmed its revenue and free cash flow guidance, which matters to shareholders because it signals higher expected adjusted profit for 2025.
Q1 2025 revenue was $3.35 billion versus $3.18 billion in Q1 2024.
Diluted EPS was $2.52 versus $2.69; adjusted EPS was $3.84 versus $3.68.
2025 adjusted EPS guidance is $15.70 to $16.40, with the midpoint raised $0.05.
Revenue guidance of 6.7% to 8.0% and free cash flow guidance of $1.10 billion to $1.25 billion were reaffirmed.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Labcorp filing is on SEC EDGAR ↗. 8-K briefs of other companies →